TROP2 ISAC / Innovent Biologics - LARVOL DELTA

Innovent Biologics' ADC Class 1 cancer drug approved for clinical trials [Google translation] (bydrug.pharmcube.com) - "According to public information from Innovent Biologics, this is an immunostimulatory antibody conjugate (ISAC) targeting TROP2. This is the first time that this product has been approved for IND in China. ISACs are a unique class of ADCs in which antibodies that recognize tumor antigens are conjugated to immune agonists. In vitro, TROP2 ISACs only mildly activate bone marrow cells in the presence of TROP2+ tumor cells."

New trial • Oncology • Solid Tumor

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting (PRNewswire) - "The anti-TROP2 antibody elicited robust ADCP of TROP2+ tumor cells by macrophages. In-vitro, TROP2 ISAC mildly activated myeloid cells only in the presence of TROP2+ tumor cells. In-vivo, the molecule potently suppressed tumor growth in different TROP2+ xenograft tumors, and effectively enhanced killing of an ADC. In terms of safety, the ISAC was tolerated in both WT and hTROP2KI mice, and, importantly, in monkeys....Taken together, our data demonstrate a novel TROP2 ISAC with outstanding efficacy and manageable safety profile, which may benefit patients with TROP2+ tumors."

Preclinical • Oncology • Solid Tumor